QNCX
Quince Therapeutics, Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$21.68M
P/E Ratio
—
EPS
$-16.80
Beta
1.33
52W High
$45.50
52W Low
$0.80
50-Day MA
$1.18
200-Day MA
$15.66
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Quince Therapeutics, Inc.
Quince Therapeutics, Inc., a biopharmaceutical company, is focused on advancing precision therapies for rare and debilitating diseases. The company is headquartered in South San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-50.29M |
| Operating Margin | 0.00% |
| Return on Equity | -247.80% |
| Return on Assets | -30.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-6.41 |
| Price-to-Book | 7.17 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.44 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $16.30M |
| Float | $15.71M |
| % Insiders | 3.19% |
| % Institutions | 13.47% |
More HEALTHCARE Stocks
Data last updated: 5/2/2026